ArticlePakistan journal of medical sciences2025
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS + HIPEC): an initial experience at a Tertiary care Hospital in Pakistan.
Article in Pakistan journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is evolving technique for advance stage malignancies. Studies have shown that CRS and HIPEC improve survival, however initial published results were not promising in view of high morbidity 20% and mortality 4.8%, hence it has yet to be standard of care for certain malignancies and further trials are awaited. This study presents outcomes of HIPEC in a Single center of a developing country. Methodology: This retrospective cross-sectional study was conducted in Shifa International Hospital, Islamabad, Pakistan. Data is collected from January 2019 to December 2023. Patients who underwent CRS and HIPEC for curative intent were included in the study. Quantitative analysis is represented by mean and standard deviation, qualitative analysis is represented by frequency and percentage. Results: Fifty patients were included. Out of these 17 (34%) were Male, and 33(66%) Female. Ovarian carcinoma was most common pathology 36%, Adenocarcinoma Colon and Low grade Appendiceal Mucinous Neoplasm 24%. No 30-day mortality was observed in our study. Recurrence was observed in 16 (32%) patients. Patient with poor tumor biology had a higher rate of recurrence (p= 0.003). Mean Overall Survival among patient who underwent HIPEC was 45±3 months. For patients who had LAMN, mean survival was 50±5 months which was significantly better than rest of pathologies. Conclusion: Cytoreduction and HIPEC offers a hope for patients with advance malignancy, however patient selection for undergoing HIPEC is of utmost importance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.